img

Global Generic and Biosimilar Pharmaceuticals Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Generic and Biosimilar Pharmaceuticals Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Generic and Biosimilar Pharmaceuticals market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Monoclonal Antibodies accounting for % of the Generic and Biosimilar Pharmaceuticals global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Tumor segment is altered to an % CAGR throughout this forecast period.
The global key companies of Generic and Biosimilar Pharmaceuticals include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Generic and Biosimilar Pharmaceuticals market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Generic and Biosimilar Pharmaceuticals landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Generic and Biosimilar Pharmaceuticals market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Generic and Biosimilar Pharmaceuticals market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Generic and Biosimilar Pharmaceuticals market. Readers of the report can become informed about current and future trends of the global Generic and Biosimilar Pharmaceuticals market and how they will impact market growth during the forecast period.



By Company


Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other

Segment by Application


Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Generic and Biosimilar Pharmaceuticals in global and regional level.
Chapter 3Detailed analysis of Generic and Biosimilar Pharmaceuticals companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic and Biosimilar Pharmaceuticals revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Market by Application
1.3.1 Global Generic and Biosimilar Pharmaceuticals Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Generic and Biosimilar Pharmaceuticals Market Size (2018-2034)
2.2 Generic and Biosimilar Pharmaceuticals Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2018-2024)
2.4 Global Generic and Biosimilar Pharmaceuticals Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Generic and Biosimilar Pharmaceuticals Countries Ranking by Market Size
3 Generic and Biosimilar Pharmaceuticals Competitive by Company
3.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Players
3.1.1 Global Generic and Biosimilar Pharmaceuticals Revenue by Players (2018-2024)
3.1.2 Global Generic and Biosimilar Pharmaceuticals Market Share by Players (2018-2024)
3.2 Global Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Generic and Biosimilar Pharmaceuticals Revenue
3.4 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio
3.4.1 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2022
3.5 Global Key Players of Generic and Biosimilar Pharmaceuticals Head office and Area Served
3.6 Global Key Players of Generic and Biosimilar Pharmaceuticals, Product and Application
3.7 Global Key Players of Generic and Biosimilar Pharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Generic and Biosimilar Pharmaceuticals Breakdown Data by Type
4.1 Global Generic and Biosimilar Pharmaceuticals Historic Revenue by Type (2018-2024)
4.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Revenue by Type (2024-2034)
5 Global Generic and Biosimilar Pharmaceuticals Breakdown Data by Application
5.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Application (2018-2024)
5.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024)
6.2 North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2034)
6.3 North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2034)
6.4 North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024)
7.2 Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2034)
7.3 Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2034)
7.4 Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024)
8.2 Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2034)
8.3 Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2034)
8.4 Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024)
9.2 Latin America Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2034)
9.3 Latin America Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2034)
9.4 Latin America Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024)
10.2 Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2034)
10.3 Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2034)
10.4 Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Generic and Biosimilar Pharmaceuticals Products and Services
11.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.1.5 Roche Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.1.6 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Generic and Biosimilar Pharmaceuticals Products and Services
11.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.2.5 Amgen Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.2.6 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Products and Services
11.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.3.5 AbbVie Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.3.6 AbbVie Recent Development
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Details
11.4.2 Sanofi-Aventis Business Overview
11.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Products and Services
11.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.4.5 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.4.6 Sanofi-Aventis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Products and Services
11.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.5.5 Johnson & Johnson Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.5.6 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Products and Services
11.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.6.5 Pfizer Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.6.6 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Products and Services
11.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.7.5 Novo Nordisk Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.7.6 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Products and Services
11.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.8.5 Eli Lilly Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.8.6 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Generic and Biosimilar Pharmaceuticals Products and Services
11.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.9.5 Novartis Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.9.6 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Generic and Biosimilar Pharmaceuticals Products and Services
11.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.10.5 Merck Generic and Biosimilar Pharmaceuticals SWOT Analysis
11.10.6 Merck Recent Development
11.11 3sbio
11.11.1 3sbio Company Details
11.11.2 3sbio Business Overview
11.11.3 3sbio Generic and Biosimilar Pharmaceuticals Products and Services
11.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.11.5 3sbio Recent Development
11.12 Changchun High Tech
11.12.1 Changchun High Tech Company Details
11.12.2 Changchun High Tech Business Overview
11.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Products and Services
11.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.12.5 Changchun High Tech Recent Development
11.13 CP Guojian
11.13.1 CP Guojian Company Details
11.13.2 CP Guojian Business Overview
11.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Products and Services
11.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.13.5 CP Guojian Recent Development
11.14 Biotech
11.14.1 Biotech Company Details
11.14.2 Biotech Business Overview
11.14.3 Biotech Generic and Biosimilar Pharmaceuticals Products and Services
11.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.14.5 Biotech Recent Development
11.15 Gelgen
11.15.1 Gelgen Company Details
11.15.2 Gelgen Business Overview
11.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Products and Services
11.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.15.5 Gelgen Recent Development
11.16 Innovent
11.16.1 Innovent Company Details
11.16.2 Innovent Business Overview
11.16.3 Innovent Generic and Biosimilar Pharmaceuticals Products and Services
11.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.16.5 Innovent Recent Development
11.17 Dong Bao
11.17.1 Dong Bao Company Details
11.17.2 Dong Bao Business Overview
11.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Products and Services
11.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.17.5 Dong Bao Recent Development
11.18 Ganlee
11.18.1 Ganlee Company Details
11.18.2 Ganlee Business Overview
11.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Products and Services
11.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
11.18.5 Ganlee Recent Development
12 Generic and Biosimilar Pharmaceuticals Market Dynamics
12.1 Generic and Biosimilar Pharmaceuticals Industry Trends
12.2 Generic and Biosimilar Pharmaceuticals Market Drivers
12.3 Generic and Biosimilar Pharmaceuticals Market Challenges
12.4 Generic and Biosimilar Pharmaceuticals Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Interferon
Table 4. Key Players of Erythropoietin
Table 5. Key Players of Insulin
Table 6. Key Players of Vaccines
Table 7. Key Players of Other
Table 8. Global Generic and Biosimilar Pharmaceuticals Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 9. Global Generic and Biosimilar Pharmaceuticals Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 10. Global Generic and Biosimilar Pharmaceuticals Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Generic and Biosimilar Pharmaceuticals Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 12. Global Generic and Biosimilar Pharmaceuticals Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 13. Global Generic and Biosimilar Pharmaceuticals Revenue by Players (2018-2024) & (US$ Million)
Table 14. Global Generic and Biosimilar Pharmaceuticals Market Share by Players (2018-2024)
Table 15. Global Top Generic and Biosimilar Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2022)
Table 16. Ranking of Global Top Generic and Biosimilar Pharmaceuticals Companies by Revenue (US$ Million) in 2022
Table 17. Global 5 Largest Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue (CR5 and HHI) & (2018-2024)
Table 18. Global Key Players of Generic and Biosimilar Pharmaceuticals, Headquarters and Area Served
Table 19. Global Key Players of Generic and Biosimilar Pharmaceuticals, Product and Application
Table 20. Global Key Players of Generic and Biosimilar Pharmaceuticals, Date of Enter into This Industry
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Generic and Biosimilar Pharmaceuticals Market Size by Type (2018-2024) & (US$ Million)
Table 23. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2024)
Table 24. Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 25. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2024-2034)
Table 26. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (2018-2024) & (US$ Million)
Table 27. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2024)
Table 28. Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 29. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2024-2034)
Table 30. North America Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024) & (US$ Million)
Table 31. North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2024) & (US$ Million)
Table 32. North America Generic and Biosimilar Pharmaceuticals Revenue by Type (2024-2034) & (US$ Million)
Table 33. North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2024) & (US$ Million)
Table 34. North America Generic and Biosimilar Pharmaceuticals Revenue by Application (2024-2034) & (US$ Million)
Table 35. North America Generic and Biosimilar Pharmaceuticals Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 36. North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2024) & (US$ Million)
Table 37. North America Generic and Biosimilar Pharmaceuticals Revenue by Country (2024-2034) & (US$ Million)
Table 38. Europe Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024) & (US$ Million)
Table 39. Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2024) & (US$ Million)
Table 40. Europe Generic and Biosimilar Pharmaceuticals Revenue by Type (2024-2034) & (US$ Million)
Table 41. Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2024) & (US$ Million)
Table 42. Europe Generic and Biosimilar Pharmaceuticals Revenue by Application (2024-2034) & (US$ Million)
Table 43. Europe Generic and Biosimilar Pharmaceuticals Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2024) & (US$ Million)
Table 45. Europe Generic and Biosimilar Pharmaceuticals Revenue by Country (2024-2034) & (US$ Million)
Table 46. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024) & (US$ Million)
Table 47. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2024) & (US$ Million)
Table 48. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Type (2024-2034) & (US$ Million)
Table 49. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2024) & (US$ Million)
Table 50. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Application (2024-2034) & (US$ Million)
Table 51. Asia-Pacific Generic and Biosimilar Pharmaceuticals Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 52. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Region (2018-2024) & (US$ Million)
Table 53. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue by Region (2024-2034) & (US$ Million)
Table 54. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024) & (US$ Million)
Table 55. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2024) & (US$ Million)
Table 56. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Type (2024-2034) & (US$ Million)
Table 57. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2024) & (US$ Million)
Table 58. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Application (2024-2034) & (US$ Million)
Table 59. Latin America Generic and Biosimilar Pharmaceuticals Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 60. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2024) & (US$ Million)
Table 61. Latin America Generic and Biosimilar Pharmaceuticals Revenue by Country (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Company (2021-2024) & (US$ Million)
Table 63. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Type (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Type (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Application (2024-2034) & (US$ Million)
Table 67. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 68. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Country (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue by Country (2024-2034) & (US$ Million)
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Generic and Biosimilar Pharmaceuticals Product and Services
Table 73. Roche Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 74. Roche Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 75. Roche Recent Development
Table 76. Amgen Company Details
Table 77. Amgen Business Overview
Table 78. Amgen Generic and Biosimilar Pharmaceuticals Product and Services
Table 79. Amgen Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 80. Amgen Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 81. Amgen Recent Development
Table 82. AbbVie Company Details
Table 83. AbbVie Business Overview
Table 84. AbbVie Generic and Biosimilar Pharmaceuticals Product and Services
Table 85. AbbVie Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 86. AbbVie Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 87. AbbVie Recent Development
Table 88. Sanofi-Aventis Company Details
Table 89. Sanofi-Aventis Business Overview
Table 90. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product and Services
Table 91. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 92. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 93. Sanofi-Aventis Recent Development
Table 94. Johnson & Johnson Company Details
Table 95. Johnson & Johnson Business Overview
Table 96. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product and Services
Table 97. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 98. Johnson & Johnson Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 99. Johnson & Johnson Recent Development
Table 100. Pfizer Company Details
Table 101. Pfizer Business Overview
Table 102. Pfizer Generic and Biosimilar Pharmaceuticals Product and Services
Table 103. Pfizer Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 104. Pfizer Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 105. Pfizer Recent Development
Table 106. Novo Nordisk Company Details
Table 107. Novo Nordisk Business Overview
Table 108. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product and Services
Table 109. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 110. Novo Nordisk Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 111. Novo Nordisk Recent Development
Table 112. Eli Lilly Company Details
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Generic and Biosimilar Pharmaceuticals Product and Services
Table 115. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 116. Eli Lilly Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 117. Eli Lilly Recent Development
Table 118. Novartis Company Details
Table 119. Novartis Business Overview
Table 120. Novartis Generic and Biosimilar Pharmaceuticals Product and Services
Table 121. Novartis Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 122. Novartis Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 123. Novartis Recent Development
Table 124. Merck Company Details
Table 125. Merck Business Overview
Table 126. Merck Generic and Biosimilar Pharmaceuticals Product and Services
Table 127. Merck Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 128. Merck Generic and Biosimilar Pharmaceuticals SWOT Analysis
Table 129. Merck Recent Development
Table 130. 3sbio Company Details
Table 131. 3sbio Business Overview
Table 132. 3sbio Generic and Biosimilar Pharmaceuticals Product and Services
Table 133. 3sbio Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 134. 3sbio Recent Development
Table 135. Changchun High Tech Company Details
Table 136. Changchun High Tech Business Overview
Table 137. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product and Services
Table 138. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 139. Changchun High Tech Recent Development
Table 140. CP Guojian Company Details
Table 141. CP Guojian Business Overview
Table 142. CP Guojian Generic and Biosimilar Pharmaceuticals Product and Services
Table 143. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 144. CP Guojian Recent Development
Table 145. Biotech Company Details
Table 146. Biotech Business Overview
Table 147. Biotech Generic and Biosimilar Pharmaceuticals Product and Services
Table 148. Biotech Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 149. Biotech Recent Development
Table 150. Gelgen Company Details
Table 151. Gelgen Business Overview
Table 152. Gelgen Generic and Biosimilar Pharmaceuticals Product and Services
Table 153. Gelgen Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 154. Gelgen Recent Development
Table 155. Innovent Company Details
Table 156. Innovent Business Overview
Table 157. Innovent Generic and Biosimilar Pharmaceuticals Product and Services
Table 158. Innovent Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 159. Innovent Recent Development
Table 160. Dong Bao Company Details
Table 161. Dong Bao Business Overview
Table 162. Dong Bao Generic and Biosimilar Pharmaceuticals Product and Services
Table 163. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 164. Dong Bao Recent Development
Table 165. Ganlee Company Details
Table 166. Ganlee Business Overview
Table 167. Ganlee Generic and Biosimilar Pharmaceuticals Product and Services
Table 168. Ganlee Generic and Biosimilar Pharmaceuticals Revenue in Generic and Biosimilar Pharmaceuticals Business (2018-2024) & (US$ Million)
Table 169. Ganlee Recent Development
Table 170. Generic and Biosimilar Pharmaceuticals Market Trends
Table 171. Generic and Biosimilar Pharmaceuticals Market Drivers
Table 172. Generic and Biosimilar Pharmaceuticals Market Challenges
Table 173. Generic and Biosimilar Pharmaceuticals Market Restraints
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Generic and Biosimilar Pharmaceuticals Product Picture
Figure 2. Global Generic and Biosimilar Pharmaceuticals Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Share by Type: 2022 VS 2034
Figure 4. Monoclonal Antibodies Features
Figure 5. Interferon Features
Figure 6. Erythropoietin Features
Figure 7. Insulin Features
Figure 8. Vaccines Features
Figure 9. Other Features
Figure 10. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 11. Global Generic and Biosimilar Pharmaceuticals Market Share by Application: 2022 VS 2034
Figure 12. Tumor
Figure 13. Diabetes
Figure 14. Cardiovascular
Figure 15. Hemophilia
Figure 16. Other
Figure 17. Generic and Biosimilar Pharmaceuticals Report Years Considered
Figure 18. Global Generic and Biosimilar Pharmaceuticals Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Generic and Biosimilar Pharmaceuticals Market Size 2018-2034 (US$ Million)
Figure 20. Global Generic and Biosimilar Pharmaceuticals Market Size Market Share by Region: 2022 VS 2034
Figure 21. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Region in 2018 VS 2022
Figure 22. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share Forecast by Region (2024-2034)
Figure 23. Global Top 10 Generic and Biosimilar Pharmaceuticals Countries Ranking by Market Size (US$ Million) in 2022
Figure 24. Global Generic and Biosimilar Pharmaceuticals Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 25. Global Generic and Biosimilar Pharmaceuticals Market Share by Players in 2022
Figure 26. Global Top Generic and Biosimilar Pharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic and Biosimilar Pharmaceuticals as of 2022)
Figure 27. The Top 10 and 5 Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2022
Figure 28. North America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company in 2022
Figure 29. North America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2034)
Figure 30. North America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2034)
Figure 31. North America Generic and Biosimilar Pharmaceuticals Revenue Share by Country (2018-2034)
Figure 32. U.S. Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 33. Canada Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 34. Europe Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company in 2022
Figure 35. Europe Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2034)
Figure 36. Europe Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2034)
Figure 37. Europe Generic and Biosimilar Pharmaceuticals Revenue Share by Country (2018-2034)
Figure 38. Germany Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 39. France Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 40. U.K. Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 41. Italy Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 42. Russia Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 43. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company in 2022
Figure 44. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2034)
Figure 45. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2034)
Figure 46. Asia Pacific Generic and Biosimilar Pharmaceuticals Revenue Share by Region (2018-2034)
Figure 47. China Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 48. Japan Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 49. South Korea Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 50. India Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 51. Australia Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 52. Taiwan Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 53. Indonesia Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 54. Thailand Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 55. Malaysia Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 56. Philippines Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 57. Vietnam Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 58. Latin America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company in 2022
Figure 59. Latin America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2034)
Figure 60. Latin America Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2034)
Figure 61. Latin America Generic and Biosimilar Pharmaceuticals Revenue Share by Country (2018-2034)
Figure 62. Mexico Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 63. Brazil Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 64. Argentina Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 65. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company in 2022
Figure 66. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue Market Share by Type (2018-2034)
Figure 67. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue Market Share by Application (2018-2034)
Figure 68. Middle East and Africa Generic and Biosimilar Pharmaceuticals Revenue Share by Country (2018-2034)
Figure 69. Turkey Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 70. Saudi Arabia Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 71. UAE Generic and Biosimilar Pharmaceuticals Revenue (2018-2034) & (US$ Million)
Figure 72. Roche Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 73. Amgen Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 74. AbbVie Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 75. Sanofi-Aventis Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 76. Johnson & Johnson Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 77. Pfizer Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 78. Novo Nordisk Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 79. Eli Lilly Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 80. Novartis Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 81. Merck Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 82. 3sbio Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 83. Changchun High Tech Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 84. CP Guojian Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 85. Biotech Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 86. Gelgen Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 87. Innovent Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 88. Dong Bao Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 89. Ganlee Revenue Growth Rate in Generic and Biosimilar Pharmaceuticals Business (2018-2024)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed